ICML 2017 | ICML 2017 session on the biosimilar rituximab: challenges and data

Christian Buske

Christian Buske, MD from the University Hospital Ulm, Ulm, Germany reviews the highlights from the symposium on rituximab, held at the International Conference on Malignant Lymphoma (ICML) 2017 in Lugano, Switzerland. Prof. Buske explains the challenges and limitations associated with the use of biosimilars. Providing clinical examples, Prof. Buske discusses recent Phase III data comparing the biosimilar rituximab to its originator in the treatment of advanced-stage follicular lymphoma (NCT02162771).
This video has been supported by Napp Pharmaceuticals Ltd through an unrestricted educational grant to Magdalen Medical Publishing.

Share this video